{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:28:07Z","timestamp":1788874087617,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017678","name":"Loyola Marymount University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101007873"],"award-info":[{"award-number":["101007873"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"IMI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012324","name":"University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"German Federal Ministry of Health","doi-asserted-by":"publisher","award":["TTU-TB 02.709"],"award-info":[{"award-number":["TTU-TB 02.709"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/s2666-5247(24)00085-5","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T10:53:45Z","timestamp":1715252025000},"page":"100869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-7712","authenticated-orcid":false,"given":"Stephen H","family":"Gillespie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-903X","authenticated-orcid":false,"given":"Sophia B","family":"Georghiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-2791","authenticated-orcid":false,"given":"Wilber","family":"Sabiiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikashmi","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Panzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-7550","authenticated-orcid":false,"given":"Irina","family":"Kontsevaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Hittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-9390","authenticated-orcid":false,"given":"Lieven J","family":"Stuyver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Bin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuong Nguyen Thuy","family":"Thuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2666-5247(24)00085-5_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/thoraxjnl-2019-214238","article-title":"Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay","volume":"75","author":"Sabiiti","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/S2666-5247(24)00085-5_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A\u00a0dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/S2666-5247(24)00085-5_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002851","article-title":"Accelerating the transition of new tuberculosis drug combinations from phase II to phase III trials: new technologies and innovative designs","volume":"16","author":"Davies","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dki376","article-title":"Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis","volume":"56","author":"Gillespie","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/S2666-5247(24)00085-5_bib8","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12916-016-0597-3","article-title":"A\u00a0new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)","volume":"14","author":"Phillips","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-13-139","article-title":"A\u00a0multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis","volume":"13","author":"Bratton","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/S2666-5247(24)00085-5_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01859-21","article-title":"Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis","volume":"60","author":"Zimmer","year":"2022","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/S2666-5247(24)00085-5_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s13063-021-05388-1","article-title":"A\u00a0systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials","volume":"22","author":"Hills","year":"2021","journal-title":"Trials"},{"key":"10.1016\/S2666-5247(24)00085-5_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2471\/BLT.23.290901","article-title":"Target product profiles: tests for tuberculosis treatment monitoring and optimization","volume":"101","author":"Gupta-Wright","year":"2023","journal-title":"Bull World Health Organ"},{"key":"10.1016\/S2666-5247(24)00085-5_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12916-016-0565-y","article-title":"Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials","volume":"14","author":"Phillips","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/rccm.200905-0661OC","article-title":"Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum","volume":"181","author":"Mukamolova","year":"2010","journal-title":"Am J Resp Crit Care"},{"key":"10.1016\/S2666-5247(24)00085-5_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72472-y","article-title":"Difference in persistent tuberculosis bacteria between in\u00a0vitro and sputum from patients: implications for translational predictions","volume":"10","author":"Faraj","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/S2666-5247(24)00085-5_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tube.2016.05.006","article-title":"Defining dormancy in mycobacterial disease","volume":"99","author":"Lipworth","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/S2666-5247(24)00085-5_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00227-21","article-title":"Tuberculosis treatment monitoring and outcome measures: new interest and new strategies","volume":"35","author":"Heyckendorf","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/S2666-5247(24)00085-5_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.5588\/ijtld.21.0515","article-title":"UNITE4TB: a new consortium for clinical drug and regimen development for TB","volume":"25","author":"Boeree","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2023.12.027","article-title":"Tuberculosis treatment monitoring tests during routine practice: study design guidance","author":"MacLean","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/S2666-5247(24)00085-5_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(13)70119-X","article-title":"Assessment of the sensitivity and specificity of Xpert MTB\/RIF assay as an early sputum biomarker of response to tuberculosis treatment","volume":"1","author":"Friedrich","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02263-2021","article-title":"Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes","volume":"60","author":"DiNardo","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/S2666-5247(24)00085-5_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03492-2020","article-title":"Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model","volume":"58","author":"Heyckendorf","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/S2666-5247(24)00085-5_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12879-023-08708-9","article-title":"A\u00a0stool based qPCR for the diagnosis of TB in children and people living with HIV in Uganda, ESwatini and Mozambique (Stool4TB): a protocol for a multicenter diagnostic evaluation","volume":"24","author":"Carratala-Castro","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib26","article-title":"High Mycobacterium tuberculosis bacillary loads detected by tuberculosis molecular bacterial load assay in patient stool: a potential alternative for non-sputum diagnosis and treatment response monitoring of tuberculosis","volume":"10","author":"Musisi","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/S2666-5247(24)00085-5_bib27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa2212537","article-title":"Treatment strategy for rifampin-susceptible tuberculosis","volume":"388","author":"Paton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0041-3879(80)90001-X","article-title":"Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination","volume":"61","author":"Aber","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/S2666-5247(24)00085-5_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0041-3879(80)90002-1","article-title":"Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa","volume":"61","author":"Mitchison","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/S2666-5247(24)00085-5_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S2213-2600(13)70231-5","article-title":"Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study","volume":"1","author":"Bryant","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib32","first-page":"241","article-title":"Timing of relapse in short-course chemotherapy trials for tuberculosis","volume":"14","author":"Nunn","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib33","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1473-3099(21)00613-7","article-title":"Can the GeneXpert MTB\/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?","volume":"22","author":"Naidoo","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10 suppl 2","key":"10.1016\/S2666-5247(24)00085-5_bib34","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/S2666-5247(24)00085-5_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12916-017-0955-9","article-title":"A\u00a0comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens","volume":"15","author":"Phillips","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/S2666-5247(24)00085-5_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1469-0691.2011.03626.x","article-title":"Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents","volume":"18","author":"Diacon","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/S2666-5247(24)00085-5_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160062","article-title":"Bacterial loads measured by the Xpert MTB\/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB","volume":"11","author":"Shenai","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/S2666-5247(24)00085-5_bib38","article-title":"Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring","volume":"9","author":"Mtafya","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/S2666-5247(24)00085-5_bib39","article-title":"Early bactericidal activity studies for pulmonary tuberculosis: a systematic review of methodological aspects","volume":"61","author":"Koele","year":"2023","journal-title":"Int\u00a0J\u00a0Antimicrob\u00a0Agents"},{"key":"10.1016\/S2666-5247(24)00085-5_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm","year":"2023","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/S2666-5247(24)00085-5_bib41","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1128\/JCM.00547-11","article-title":"Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment","volume":"49","author":"Honeyborne","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/S2666-5247(24)00085-5_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.37.2.290-295.1999","article-title":"Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis","volume":"37","author":"Hellyer","year":"1999","journal-title":"J\u00a0Clin Microbiol"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:33:06Z","timestamp":1725402786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524724000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666524724000855"],"URL":"https:\/\/doi.org\/10.1016\/s2666-5247(24)00085-5","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2666-5247(24)00085-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100869"}}